Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2014 (2014), Article ID 472949, 8 pages
Research Article

Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study

1Department of Urology, University of Pisa, 56126 Pisa, Italy
2Skåne University Hospital, SE 205 02 Malmö, Sweden
3Hospital Ramon y Cajal, 28034 Madrid, Spain
4GlaxoSmithKline, Research Triangle Park, NC 27709, USA
5GlaxoSmithKline, Urology Centre of Excellence, C/Severo Ochoa 2, Tres Cantos, 28760 Madrid, Spain
6GlaxoSmithKline, Health Outcomes Studies, 78160 Marly-Le-Roi, France
7GlaxoSmithKline, King of Prussia, PA 19406, USA

Received 21 October 2013; Revised 29 January 2014; Accepted 29 January 2014; Published 13 March 2014

Academic Editor: Michael Zelefsky

Copyright © 2014 Cesare Selli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. To assess the impact of low-to-moderate risk prostate cancer on patients’ quality of life (QoL) at diagnosis and within the first year of treatment. Subjects and Methods. Men () aged 50–75 years with prostate cancer (Gleason score , PSA  ng/mL and clinical staging T1c–T2b) were enrolled in five European countries. Patients completed five questionnaires, including EORTC Quality of Life Questionnaire—Prostate Cancer 25 (QLQ-PR25) and EORTC Quality of Life Questionnaire—Cancer 30 (QLQ-C30). Questionnaires were completed at baseline, at 3 months and 12 months after starting treatment. The primary endpoint was the change in QLQ-PR25 urinary symptoms subscale score from baseline to the assessment at 3 months. Results. Mean (SD) age was 65.0 (5.7) years and 400 (66%) men had Gleason score ≤6 prostate cancer. The most frequently used initial treatment was radical prostatectomy (71% of patients). QLQ-PR25 urinary symptoms subscale score was significantly increased at 3 months (), indicating that urinary symptoms worsened after treatment. The score was lower at 12 months than at 3 months, but it was still significantly higher than at baseline (). Hormonal treatment-related symptoms, sexual functioning, and sexual activity scores significantly worsened at 3 and 12 months (all ). For the QLQ-C30 questionnaire, global health status/QoL score significantly decreased at month 3 but was not different from baseline by month 12. Scales for physical, role, and social functioning, and fatigue, showed significant deterioration at 3 and 12 months. Conclusions. Low-to-moderate risk prostate cancer may have a substantial effect on patients’ QoL within one year following treatment.